PRN Therapeutics launches nūretin®
BLUE BELL, Pa., March 13, 2018 /PRNewswire/ -- PRN Therapeutics, the world's leading producer of condition-specific eye care products, today announced the launch of a novel medical food formulated to reduce the risk of and slow the progression to diabetic retinopathy. The new product, nuretin, is a purified triglyceride form (rTG) omega-3 providing 1200 mgs of EPA and DHA in a 1:5 ratio. With over 30 million people in the United States living with diabetes and another 84 million adults that are pre-diabetic, the rate of diabetic retinopathy is growing rapidly. According to The American Diabetes Association, 60% of adults with type II diabetes present with some form of diabetic retinopathy within 20 years from diagnosis. nuretin will be the first non-prescription, evidence-based medical food for this patient population that must be distributed through the recommendation of physicians.
Ken Krieg, CEO of PRN Therapeutics noted, "We are excited to bring this much needed therapeutic solution to the ophthalmic and optometric communities. The launch of nuretin comes at a perfect time for the immense population of aging baby-boomers who are being diagnosed with diabetes. nuretin will provide an essential therapeutic tool for eyecare professionals and physicians seeking to provide intervention to retinopathy among their diabetic patients."
nuretin is supported by significant peer-reviewed research including published studies in Diabetes Care, National Institutes of Health, JAMA Ophthalmology, and Retina.
Dr. Mitchell Fineman, Retina Specialist commented, "nuretin is revolutionary in this space. The clinical data supporting the product and the growing number of patients at risk for diabetic retinopathy make it a valuable addition to current treatment recommendations for a large proportion of diabetic patients."
nuretin is available exclusively through a doctor recommendation and direct delivery by PRN Therapeutics. PRN Therapeutics is currently providing webinars and other educational materials to enable patient access to nuretin and meet the strong demand as quickly as possible.
About PRN Therapeutics
PRN Therapeutics is the leading producer of condition-specific omega-3 products and macular vitamins specifically formulated to improve ocular health. Developed by doctors and recommended by world-renowned medical thought leaders, PRN's products are supported by medical evidence and offer exceptional quality and purity. PRN is one of the fastest growing privately held companies and has appeared on the INC 5000 list for five years in a row. Visit prntherapeutics.com to learn more.
CONTACT: Beth Pearson, Marketing Director, PRN Therapeutics, 610.234.4397
View original content with multimedia: http://www.prnewswire.com/news-releases/prn-therapeutics-launches-nretin-300612745.html
SOURCE PRN Therapeutics